Drug intelligence / Profile preview

CD30 biAb-AATC

Development stage: Phase 1
Lead developer: Medical College of Wisconsin
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cell Therapies
Administration: Intravenous

Overview

CD30 biAb-AATC (CD30 bispecific antibody-armed anti-CD3-activated autologous T-cells) is an immunotherapy that combines a novel CD30 antibody conjugated to a CD3 antibody preloaded onto a patient's own T-cells. This approach harnesses the dual specificity of the bispecific antibody, the power of cellular therapy, and the safety of non-genetically modified autologous T cell infusions. The therapy is designed to target CD30-positive malignancies including Hodgkin lymphoma and various types of non-Hodgkin lymphomas.

Other names: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cellsanti-CD-30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cellsanti-CD 30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells

Targets

CD30 (CD30 antigen)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on CD30 biAb-AATC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD30 biAb-AATC.

Explore the full profile